Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma

被引:40
|
作者
Siegel, Matthew B. [1 ]
Liu, Selina Qiuying [1 ]
Davare, Monika A. [1 ,2 ]
Spurgeon, Stephen E. [1 ]
Loriaux, Marc M. [1 ]
Druker, Brian J. [1 ,3 ]
Scott, Emma C. [1 ]
Tyner, Jeffrey W. [1 ]
机构
[1] Knight Canc Inst, Portland, OR 97239 USA
[2] Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97201 USA
[3] Howard Hughes Med Inst, Portland, OR USA
关键词
BET; bromodomain; bortezomib; resistance; myeloma; MANTLE CELL LYMPHOMA; MULTIPLE-MYELOMA; C-MYC; PROTEASOME INHIBITION; THERAPEUTIC TARGET; BET BROMODOMAINS; ER STRESS; IN-VITRO; APOPTOSIS; NVP-BEZ235;
D O I
10.18632/oncotarget.4214
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Despite significant therapeutic progress in multiple myeloma, drug resistance is uniformly inevitable and new treatments are needed. Our aim was to identify novel, efficacious small-molecule combinations for use in drug resistant multiple myeloma. Experimental Design: A panel of 116 small molecule inhibitors was used to screen resistant myeloma cell lines for potential therapeutic targets. Agents found to have enhanced activity in the bortezomib or melphalan resistant myeloma cell lines were investigated further in combination. Synergistic combinations of interest were evaluated in primary patient cells. Results: The overall single-agent drug sensitivity profiles were dramatically different between melphalan and bortezomib resistant cells, however, the bromodomain inhibitor, CPI203, was observed to have enhanced activity in both the bortezomib and melphalan resistant lines compared to their wild-type counterparts. The combination of bortezomib and CPI203 was found to be synergistic in both the bortezomib and melphalan resistant cell lines as well as in a primary multiple myeloma sample from a patient refractory to recent proteasome inhibitor treatment. The CPI203-bortezomib combination led to enhanced apoptosis and anti-proliferative effects. Finally, in contrast to prior reports of synergy between bortezomib and other epigenetic modifying agents, which implicated MYC downregulation or NOXA induction, our analyses suggest that CPI203-bortezomib synergy is independent of these events. Conclusion: Our preclinical data supports a role for the clinical investigation of the bromodomain inhibitor CPI203 combined with bortezomib or alkylating agents in resistant multiple myeloma.
引用
收藏
页码:18921 / 18932
页数:12
相关论文
共 50 条
  • [41] Differential synergistic anti-myeloma effects of the COX-2 inhibitor NS398, and bortezomib on doxorubicin-sensitive and resistant myeloma cells.
    Yang, HH
    Yan, XM
    Chen, HM
    Berenson, JR
    BLOOD, 2003, 102 (11) : 936A - 937A
  • [42] A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance
    Chauhan, Dharminder
    Tian, Ze
    Nicholson, Benjamin
    Kumar, K. G. Suresh
    Zhou, Bin
    Carrasco, Ruben
    McDermott, Jeffrey L.
    Leach, Craig A.
    Fulcinniti, Mariaterresa
    Kodrasov, Matthew P.
    Weinstock, Joseph
    Kingsbury, William D.
    Hideshima, Teru
    Shah, Parantu K.
    Minvielle, Stephane
    Altun, Mikael
    Kessler, Benedikt M.
    Orlowski, Robert
    Richardson, Paul
    Munshi, Nikhil
    Anderson, Kenneth C.
    CANCER CELL, 2012, 22 (03) : 345 - 358
  • [43] The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance
    Chauhan, D
    Li, G
    Podar, K
    Hideshima, T
    Shringarpure, R
    Catley, L
    Mitsiades, C
    Munshi, N
    Tai, YT
    Suh, N
    Gribble, GW
    Honda, T
    Schlossman, R
    Richardson, P
    Sporn, MB
    Anderson, KC
    BLOOD, 2004, 103 (08) : 3158 - 3166
  • [44] In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells
    McKenzie, Brienne A.
    Zemp, Franz J.
    Pisklakova, Alexandra
    Narendran, Aru
    McFadden, Grant
    Lun, Xueqing
    Kenchappa, Rajappa S.
    Kurz, Ebba U.
    Forsyth, Peter A.
    NEURO-ONCOLOGY, 2015, 17 (08) : 1086 - 1094
  • [45] High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma
    Stessman, H. A. F.
    Lulla, A.
    Xia, T.
    Mitra, A.
    Harding, T.
    Mansoor, A.
    Myers, C. L.
    Van Ness, B. G.
    Dolloff, N. G.
    LEUKEMIA, 2014, 28 (11) : 2263 - 2267
  • [46] High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma
    H A F Stessman
    A Lulla
    T Xia
    A Mitra
    T Harding
    A Mansoor
    C L Myers
    B G Van Ness
    N G Dolloff
    Leukemia, 2014, 28 : 2263 - 2267
  • [47] Small Molecule Kinase Inhibitor Screen Identifies Polo-Like Kinase 1 as a Target for Neuroblastoma Tumor-Initiating Cells
    Grinshtein, Natalie
    Datti, Alessandro
    Fujitani, Mayumi
    Uehling, David
    Prakesch, Michael
    Isaac, Methvin
    Irwin, Meredith S.
    Wrana, Jeffrey L.
    Al-awar, Rima
    Kaplan, David R.
    CANCER RESEARCH, 2011, 71 (04) : 1385 - 1395
  • [48] Small-molecule screening identifies the selanazal drug ebselen as a potent inhibitor of DMT1-mediated iron uptake
    Wetli, Herbert A.
    Buckett, Peter D.
    Wessling-Resnick, Marianne
    CHEMISTRY & BIOLOGY, 2006, 13 (09): : 965 - 972
  • [49] A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance
    Tian, Ze
    D'Arcy, Padraig
    Wang, Xin
    Ray, Arghya
    Tai, Yu-Tzu
    Hu, Yiguo
    Carrasco, Ruben D.
    Richardson, Paul
    Linder, Stig
    Chauhan, Dharminder
    Anderson, Kenneth C.
    BLOOD, 2014, 123 (05) : 706 - 716
  • [50] A Novel Small Molecule Inhibitor Of Deubiquitylating Enzyme USP14 and UCHL5 Induces Apoptosis In Myeloma Cells and Overcomes Bortezomib Resistance
    Tian, Ze
    D'Arcy, Padraig
    Wang, Xin
    Ray, Arghya
    Tai, Yu-Tzu
    Hu, Yiguo
    Carrasco, Ruben
    Das, Deepika
    Richardson, Paul
    Linder, Stig
    Chauhan, Dharminder
    Anderson, Kenneth C.
    BLOOD, 2013, 122 (21)